Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage
See all results for  

anp

ATL1102 for MS further development plans
Antisense Therapeutics Limited ("ANP" or "the Company") is pleased to advise that it has received the US Food and Drug Administration's (FDA) response to the Company's formal request for a Pre-Investigational New Drug (Pre-IND) assessment of ANP's ...
 Noodls1 day ago
ATL1103 Acromegaly Phase II Trial Results
Antisense Therapeutics Limited ("ANP") is pleased to confirm that primary efficacy results for the Phase II trial of ATL1103 for the growth disorder, acromegaly are on track to be received by the Company by the close of business Friday 29 August UK ...
 Noodls1 week ago
ANP reports primary efficacy results from ATL1103 Phase II trial in patients with acromegaly
Aviv acquires assisted living and skilled nursing facilities for $83.6 million Organizations across U.S. participating in Go Gold for Childhood Cancer Awareness campaign XBiotech reports interim results from Phase III study for anti-cancer agent ...
 News-Medical.Net2 weeks ago
ISIS Pharmaceuticals : ATL1103 Phase II Trial - Successful Efficacy Results
TOORAK, Australia, Sept. 2, 2014 /PRNewswire/ -- Antisense Therapeutics Limited ("ANP" or "the Company") is pleased to report the primary efficacy results from its Phase II clinical trial of ATL1103 in patients with the potentially life threatening ...
 4 Traders2 weeks ago
ATL1103 Phase II Trial - Successful Efficacy Results
]]> TOORAK, Australia , Sept. 2, 2014 /PRNewswire/ -- Antisense Therapeutics Limited ("ANP" or "the Company") is pleased to report the primary efficacy results from its Phase II clinical trial of ATL1103 in patients with the potentially life ...
 Sys-Con Italia2 weeks ago
ATL1103 Phase II Trial Successful Efficacy Results
TOORAK, Australia , Sept. 2, 2014 /NEWS.GNOM.ES/ — Antisense Therapeutics Limited (ANP or the Company) is pleased to report the primary efficacy results from its Phase II clinical trial of ATL1103 in patients with the potentially life threatening ...
 Gnom.es2 weeks ago
Antisense Therapeutics : ATL1102 for MS further development plans
_ATL1102 MS pre IND FDA response European patent allowance_Final 16 September 2014 ATL1102 for MS further development plans - US FDA Pre-IND response timing confirmed; European Patent Allowance Antisense Therapeutics Limited ("ANP" or "the ...
 4 Traders1 day ago
Antisense Therapeutics : ATL1103 Acromegaly Phase II Trial Results
ATL1103 Phase II Results_final 28 August 2014 ATL1103 Acromegaly Phase II Trial Results Antisense Therapeutics Limited ("ANP") is pleased to confirm that primary efficacy results for the Phase II trial of ATL1103 for the growth disorder, ...
 4 Traders1 week ago
Antisense Therapeutics Limited announces ATL1103 Phase II Trial successful efficacy results
3:30am BST Antisense Therapeutics Limited:Announces primary efficacy results from its Phase II clinical trial of ATL1103 in patients with the potentially life threatening growth disorder, acromegaly.Says the Phase II trial met its primary efficacy ...
 Reuters UK2 weeks ago
ATL1103 Phase II Trial - Successful Efficacy Results
Antisense Therapeutics Limited ("ANP" or "the Company") is pleased to report the primary efficacy results from its Phase II clinical trial of ATL1103 in patients with the potentially life threatening growth disorder, acromegaly. The Phase II trial ...
 Individual.com2 weeks ago
ATL1103 Phase II Trial - Successful Efficacy Results
TOORAK, Australia, Sept. 2, 2014 /PRNewswire/ -- Antisense Therapeutics Limited ("ANP" or "the Company") is pleased to report the primary efficacy results from its Phase II clinical trial of ATL1103 in patients with the potentially life threatening ...
 Yahoo! Finance2 weeks ago
ATL1103 Phase II Trial - Successful Efficacy Results
TOORAK, Australia , Sept. 2, 2014 /PRNewswire/ -- Antisense Therapeutics Limited ("ANP" or "the Company") is pleased to report the primary efficacy results from its Phase II clinical trial of ATL1103 in patients with the potentially life threatening ...
 ADVFN India2 weeks ago
ATL1103 Phase II Trial - Successful Efficacy Results
TOORAK, Australia, Sept. 2, 2014 /PRNewswire/ -- Antisense Therapeutics Limited ("ANP" or "the Company") is pleased to report the primary efficacy results from its Phase II clinical trial of ATL1103 in patients with the potentially life threatening ...
 Sys-Con Belgium2 weeks ago
ATL1103 Phase II Trial - Successful Efficacy Results
TOORAK, Australia, Sept. 2, 2014 /PRNewswire/ -- Antisense Therapeutics Limited ("ANP" or "the Company") is pleased to report the primary efficacy results from its Phase II clinical trial of ATL1103 in patients with the potentially life threatening ...
 Sys-Con Australia2 weeks ago
ATL1103 Phase II Trial - Successful Efficacy Results
TOORAK, Australia , Sept. 2, 2014 /PRNewswire/ -- Antisense Therapeutics Limited ("ANP" or "the Company") is pleased to report the primary efficacy results from its Phase II clinical trial of ATL1103 in patients with the potentially life threatening ...
 CEOWorld Magazine2 weeks ago
ATL1103 Phase II Trial - Successful Efficacy Results
TOORAK, Australia , Sept. 2, 2014 /PRNewswire/ -- Antisense Therapeutics Limited ("ANP" or "the Company") is pleased to report the primary efficacy results from its Phase II clinical trial of ATL1103 in patients with the potentially life threatening ...
 Crawford Financial Planning2 weeks ago
ATL1103 Phase II Trial - Successful Efficacy Results
TOORAK, Australia , Sept. 2, 2014 /PRNewswire/ -- Antisense Therapeutics Limited ("ANP" or "the Company") is pleased to report the primary efficacy results from its Phase II clinical trial of ATL1103 in patients with the potentially life threatening ...
 Reliance Trust2 weeks ago
ATL1103 Phase II Trial - Successful Efficacy Results
TOORAK, Australia , Sept. 2, 2014 /PRNewswire/ -- Antisense Therapeutics Limited ("ANP" or "the Company") is pleased to report the primary efficacy results from its Phase II clinical trial of ATL1103 in patients with the potentially life threatening ...
 Minyanville2 weeks ago
ATL1103 Phase II Trial - Successful Efficacy Results
TOORAK, Australia , Sept. 2, 2014 /PRNewswire/ -- Antisense Therapeutics Limited ("ANP" or "the Company") is pleased to report the primary efficacy results from its Phase II clinical trial of ATL1103 in patients with the potentially life threatening ...
 Street Sweeper2 weeks ago
ATL1103 Phase II Trial - Successful Efficacy Results
TOORAK, Australia , Sept. 2, 2014 /PRNewswire/ -- Antisense Therapeutics Limited ("ANP" or "the Company") is pleased to report the primary efficacy results from its Phase II clinical trial of ATL1103 in patients with the potentially life threatening ...
 Market Pulse Navigator2 weeks ago
ATL1103 Phase II Trial - Successful Efficacy Results
TOORAK, Australia , Sept. 2, 2014 /PRNewswire/ -- Antisense Therapeutics Limited ("ANP" or "the Company") is pleased to report the primary efficacy results from its Phase II clinical trial of ATL1103 in patients with the potentially life threatening ...
 Wall Street Business Network2 weeks ago
ATL1103 Phase II Trial - Successful Efficacy Results
TOORAK, Australia , Sept. 2, 2014 /PRNewswire/ -- Antisense Therapeutics Limited ("ANP" or "the Company") is pleased to report the primary efficacy results from its Phase II clinical trial of ATL1103 in patients with the potentially life threatening ...
 Tamar Securities2 weeks ago
ATL1103 Phase II Trial - Successful Efficacy Results
TOORAK, Australia , Sept. 2, 2014 /PRNewswire/ -- Antisense Therapeutics Limited ("ANP" or "the Company") is pleased to report the primary efficacy results from its Phase II clinical trial of ATL1103 in patients with the potentially life threatening ...
 A.M. Best2 weeks ago
ATL1103 Phase II Trial - Successful Efficacy Results
TOORAK, Australia, Sept. 2, 2014 /PRNewswire/ -- Antisense Therapeutics Limited ("ANP" or "the Company") is pleased to report the primary efficacy results from its Phase II clinical trial of ATL1103 in patients with the potentially life threatening ...
 Nasdaq2 weeks ago
ATL1103 Phase II Trial - Successful Efficacy Results
TOORAK, Australia, Sept. 2, 2014 /PRNewswire/ -- Antisense Therapeutics Limited ("ANP" or "the Company") is pleased to report the primary efficacy results from its Phase II clinical trial of ATL1103 in patients with the potentially life threatening ...
 Financial Content2 weeks ago
ATL1103 Phase II Trial - Successful Efficacy Results
TOORAK, Australia , Sept. 2, 2014 /PRNewswire/ -- Antisense Therapeutics Limited ("ANP" or "the Company") is pleased to report the primary efficacy results from its Phase II clinical trial of ATL1103 in patients with the potentially life threatening ...
 Securities Technology Monitor2 weeks ago
ATL1103 Phase II Trial - Successful Efficacy Results
TOORAK, Australia , Sept. 2, 2014 /PRNewswire/ -- Antisense Therapeutics Limited ("ANP" or "the Company") is pleased to report the primary efficacy results from its Phase II clinical trial of ATL1103 in patients with the potentially life threatening ...
 Fat Pitch Financials2 weeks ago
ATL1103 Phase II Trial - Successful Efficacy Results
TOORAK, Australia , Sept. 2, 2014 /PRNewswire/ -- Antisense Therapeutics Limited ("ANP" or "the Company") is pleased to report the primary efficacy results from its Phase II clinical trial of ATL1103 in patients with the potentially life threatening ...
 MoneyShow.com2 weeks ago
ATL1103 Phase II Trial - Successful Efficacy Results
TOORAK, Australia , Sept. 2, 2014 /PRNewswire/ -- Antisense Therapeutics Limited ("ANP" or "the Company") is pleased to report the primary efficacy results from its Phase II clinical trial of ATL1103 in patients with the potentially life threatening ...
 SearchBug2 weeks ago
ATL1103 Phase II Trial - Successful Efficacy Results
TOORAK, Australia , Sept. 2, 2014 /PRNewswire/ -- Antisense Therapeutics Limited ("ANP" or "the Company") is pleased to report the primary efficacy results from its Phase II clinical trial of ATL1103 in patients with the potentially life threatening ...
 TVNewsCheck2 weeks ago
ATL1103 Phase II Trial - Successful Efficacy Results
TOORAK, Australia , Sept. 2, 2014 /PRNewswire/ -- Antisense Therapeutics Limited ("ANP" or "the Company") is pleased to report the primary efficacy results from its Phase II clinical trial of ATL1103 in patients with the potentially life threatening ...
 Town Hall2 weeks ago
ATL1103 Phase II Trial - Successful Efficacy Results
TOORAK, Australia , Sept. 2, 2014 /PRNewswire/ -- Antisense Therapeutics Limited ("ANP" or "the Company") is pleased to report the primary efficacy results from its Phase II clinical trial of ATL1103 in patients with the potentially life threatening ...
 Franklin Credit Management Corporation2 weeks ago
ATL1103 Phase II Trial - Successful Efficacy Results
TOORAK, Australia , Sept. 2, 2014 /PRNewswire/ -- Antisense Therapeutics Limited ("ANP" or "the Company") is pleased to report the primary efficacy results from its Phase II clinical trial of ATL1103 in patients with the potentially life threatening ...
 WorldNetDaily2 weeks ago
ATL1103 Phase II Trial - Successful Efficacy Results
TOORAK, Australia , Sept. 2, 2014 /PRNewswire/ -- Antisense Therapeutics Limited ("ANP" or "the Company") is pleased to report the primary efficacy results from its Phase II clinical trial of ATL1103 in patients with the potentially life threatening ...
 RCL Advisors2 weeks ago
ATL1103 Phase II Trial - Successful Efficacy Results
TOORAK, Australia , Sept. 2, 2014 /PRNewswire/ -- Antisense Therapeutics Limited ("ANP" or "the Company") is pleased to report the primary efficacy results from its Phase II clinical trial of ATL1103 in patients with the potentially life threatening ...
 Vision Monday2 weeks ago
ATL1103 Phase II Trial - Successful Efficacy Results
TOORAK, Australia , Sept. 2, 2014 /PRNewswire/ -- Antisense Therapeutics Limited ("ANP" or "the Company") is pleased to report the primary efficacy results from its Phase II clinical trial of ATL1103 in patients with the potentially life threatening ...
 BioSpace2 weeks ago
ATL1103 Phase II Trial - Successful Efficacy Results
TOORAK, Australia, Sept. 2, 2014 /PRNewswire/ -- Antisense Therapeutics Limited ("ANP" or "the Company") is pleased to report the primary efficacy results from its Phase II clinical trial of ATL1103 in patients with the potentially life threatening ...
 TickerTech.com2 weeks ago
Antisense Therapeutics Limited Release: ATL1103 Phase 2 Trial - Successful Efficacy Results
Primary efficacy endpoint met with a statistically significant reduction of sIGF-I levels of 26% at the 400mg/week dose - Safe and well tolerated with no serious adverse events related to dosing reported TOORAK, Australia , Sept. 2, 2014 ...
 BioSpace1 week ago
ATL1103 Phase II Trial - Successful Efficacy Results
- Primary efficacy endpoint met with a statistically significant reduction of sIGF-I levels of 26% at the 400mg/week dose (P<0.0001; highly significant) - 36% average reduction in sIGF-I for lower body weight patients - Positioned to move into ...
 PipelineReview2 weeks ago
ATL1103 Phase II Trial - Successful Efficacy Results
Company News: Page (1) of 1 - 09/02/14 print page - Primary efficacy endpoint met with a statistically significant reduction of sIGF-I levels of 26% at the 400mg/week dose (P<0.0001; highly significant)- 36% average reduction in sIGF-I for ...
 Tutorial Finder2 weeks ago
ATL1103 Phase II Trial - Successful Efficacy Results
Company News: Page (1) of 1 - 09/02/14 print page - Primary efficacy endpoint met with a statistically significant reduction of sIGF-I levels of 26% at the 400mg/week dose (P<0.0001; highly significant)- 36% average reduction in sIGF-I for ...
 Review Seeker2 weeks ago
ATL1103 Phase II Trial - Successful Efficacy Results
- Primary efficacy endpoint met with a statistically significant reduction of sIGF-I levels of 26% at the 400mg/week dose (P Sep. 2, 2014 07:20 PM TOORAK, Australia , Sept. 2, 2014 /PRNewswire/ -- Antisense Therapeutics Limited ("ANP" or ...
 Sys-Con India2 weeks ago
ATL1103 Phase II Trial - Successful Efficacy Results
- Primary efficacy endpoint met with a statistically significant reduction of sIGF-I levels of 26% at the 400mg/week dose (P!!!!0.0001; highly significant)- 36% average reduction in sIGF-I for lower body weight patients- Positioned to move into ...
 PredictWallStreet2 weeks ago
ATL1103 Phase II Trial - Successful Efficacy Results
• Primary efficacy endpoint met with a statistically significant reduction of sIGF-I levels of 26% at the 400mg/week dose (P0.0001; highly significant) • 36% average reduction in sIGF-I for lower body weight patients • Positioned to move ...
 Noodls2 weeks ago
ATL1103 Phase II Trial - Successful Efficacy Results
Related Stocks ISIS - Isis Pharmaceuticals Sym Last Chg Pct Volume ISIS40.73-0.03-0.07%2,140,552 TOORAK, Australia , Sept. 2, 2014 /PRNewswire/ -- Antisense Therapeutics Limited ("ANP" or "the Company") is pleased to report the primary efficacy ...
 Barchart2 weeks ago
ATL1103 Phase II Trial - Successful Efficacy Results
TOORAK, Australia All patients treated with 400mg per week of ATL1103 had a reduction in sIGF-I levels from baseline at week 14. Greater reductions in sIGF-I were observed in patients who had lower body weights and thereby received a relatively ...
 TheStreet.com2 weeks ago
ATL1103 Phase II Trial - Successful Efficacy Results
TOORAK, Australia All patients treated with 400mg per week of ATL1103 had a reduction in sIGF-I levels from baseline at week 14. Greater reductions in sIGF-I were observed in patients who had lower body weights and thereby received a relatively ...
 Benzinga.com2 weeks ago
ATL1103 Phase II Trial - Successful Efficacy Results
- 36% average reduction in sIGF-I for lower body weight patients - Positioned to move into Phase III stage of development - Safe and well tolerated with no serious adverse events related to dosing reported TOORAK, Australia , Sept. 2, 2014 ...
 Morningstar.com2 weeks ago
ATL1103 Phase II Trial - Successful Efficacy Results
TOORAK, Australia All patients treated with 400mg per week of ATL1103 had a reduction in sIGF-I levels from baseline at week 14. Greater reductions in sIGF-I were observed in patients who had lower body weights and thereby received a relatively ...
 Stock Nod2 weeks ago
ATL1103 Phase II Trial - Successful Efficacy Results
09/02 18:19 CDT - Primary efficacy endpoint met with a statistically significant reduction of sIGF-I levels of 26% at the 400mg/week dose (P<0.0001; highly significant)- 36% average reduction in sIGF-I for lower body weight patients- Positioned ...
 Finwin2 weeks ago
ATL1103 Phase II Trial - Successful Efficacy Results
All patients treated with 400mg per week of ATL1103 had a reduction in sIGF-I levels from baseline at week 14. Greater reductions in sIGF-I were observed in patients who had lower body weights and thereby received a relatively higher dose per kg ...
 Wall Street Select2 weeks ago
ATL1103 Phase II Trial - Successful Efficacy Results
- Primary efficacy endpoint met with a statistically significant reduction of sIGF-I levels of 26% at the 400mg/week dose (P<0.0001; highly significant) - 36% average reduction in sIGF-I for lower body weight patients - Positioned to move into ...
 Reuters2 weeks ago
ATL1103 Phase II Trial - Successful Efficacy Results
TOORAK, Australia All patients treated with 400mg per week of ATL1103 had a reduction in sIGF-I levels from baseline at week 14. Greater reductions in sIGF-I were observed in patients who had lower body weights and thereby received a relatively ...
 ADVFN UK2 weeks ago
ATL1103 Phase II Trial - Successful Efficacy Results
All patients treated with 400mg per week of ATL1103 had a reduction in sIGF-I levels from baseline at week 14. Greater reductions in sIGF-I were observed in patients who had lower body weights and thereby received a relatively higher dose per kg ...
 Industrial Info Financials2 weeks ago
ATL1103 Phase II Trial - Successful Efficacy Results
PR Newswire TOORAK, Australia, Sept. 2, 2014 TOORAK, Australia All patients treated with 400mg per week of ATL1103 had a reduction in sIGF-I levels from baseline at week 14. Greater reductions in sIGF-I were observed in patients who had lower ...
 Digital Journal2 weeks ago
ATL1103 Phase II Trial - Successful Efficacy Results
All patients treated with 400mg per week of ATL1103 had a reduction in sIGF-I levels from baseline at week 14. Greater reductions in sIGF-I were observed in patients who had lower body weights and thereby received a relatively higher dose per kg ...
 Pettinga Financial Advisors2 weeks ago
ATL1103 Phase II Trial - Successful Efficacy Results
- Primary efficacy endpoint met with a statistically significant reduction of sIGF-I levels of 26% at the 400mg/week dose (P<0.0001; highly significant) - 36% average reduction in sIGF-I for lower body weight patients - Positioned to move into ...
 Stockwatch2 weeks ago

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
Happening by Location Click on any location on map to view latest news by location